KRTX News and Press, Karuna Therapeutics Inc. From 02/02/23

Karuna Therapeutics ( NASDAQ: KRTX ) signed an agreement to get global development, manufacturing, and sale rights to Goldfinch Bio's investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead drug GFB-887. Karuna plans to evaluate thes...

Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to receive $15 million upfront payment and up to $520 million in potential milestone payments plus ...

Karuna Therapeutics ( NASDAQ: KRTX ) appointed Will Kane as chief commercial officer (CCO), effective Feb. 6. Most recently, Kane served as the executive vice president and CCO at BioXcel Therapeutics ( NASDAQ: BTAI ). Kane has over 30 years of experience i...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Will Kane as chief commercial officer (CCO), effective Febr...

Summary Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February. The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatm...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Bill Meury, president and chief executive officer, will present at the 41...

Summary Smallcaps are the first ones to get affected by the recession and the last ones to show recovery. Key fundamental drivers of the VTWO ETF are rising interest rates, recession, and overall bearish sentiments of the markets. My technical analysis framework based on Trend Flow,...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...